It has been reported that dopamine D4 receptor antagonist can suppress microglial activation and delay the progression of amyotrophic lateral sclerosis (ALS) (Tanaka et al., 2008). This evidence concerns the gene DRD4 and amyotrophic lateral sclerosis.